PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pulmonary nocardiosis in an adolescent patient with Crohn's disease treated with infliximab: a serious complication of TNF-alpha blockers.

Abstract Nocardiosis is a serious complication of tumor necrosis factor (TNF) alpha blockers. With the increasing use of biologics for inflammatory bowel disease, it is to be anticipated that opportunistic infections such as nocardia will be more frequently encountered in children. We present the case of a 16 year old male with Crohn's disease who developed pulmonary nocardiosis during the course of his treatment with infliximab. This case illustrates the diagnostic and therapeutic challenges faced in patients with inflammatory bowel disease infected with opportunistic organisms. Pediatric health care providers need to be aware so that early diagnosis and treatment can be provided thereby preventing disseminated disease and having favorable outcomes. Although TNF blocker therapy must be discontinued in the presence of such infections, biologic therapy may be reintroduced after successful treatment with trimethoprim-sulfamethoxazole to control underlying symptoms of inflammatory bowel disease.
PMID
Related Publications

Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone.

A case of liver nocardiosis associated with Crohn's disease while treating infliximab.

Risk of nocardial infections with anti-tumor necrosis factor therapy.

Authors

Mayor MeshTerms
Keywords
Journal Title the west virginia medical journal
Publication Year Start




PMID- 26050296
OWN - NLM
STAT- MEDLINE
DCOM- 20150619
LR  - 20170220
IS  - 0043-3284 (Print)
IS  - 0043-3284 (Linking)
VI  - 111
IP  - 3
DP  - 2015 May-Jun
TI  - Pulmonary nocardiosis in an adolescent patient with Crohn's disease treated with 
      infliximab: a serious complication of TNF-alpha blockers.
PG  - 36-9
AB  - Nocardiosis is a serious complication of tumor necrosis factor (TNF) alpha
      blockers. With the increasing use of biologics for inflammatory bowel disease, it
      is to be anticipated that opportunistic infections such as nocardia will be more 
      frequently encountered in children. We present the case of a 16 year old male
      with Crohn's disease who developed pulmonary nocardiosis during the course of his
      treatment with infliximab. This case illustrates the diagnostic and therapeutic
      challenges faced in patients with inflammatory bowel disease infected with
      opportunistic organisms. Pediatric health care providers need to be aware so that
      early diagnosis and treatment can be provided thereby preventing disseminated
      disease and having favorable outcomes. Although TNF blocker therapy must be
      discontinued in the presence of such infections, biologic therapy may be
      reintroduced after successful treatment with trimethoprim-sulfamethoxazole to
      control underlying symptoms of inflammatory bowel disease.
FAU - Verma, Rishi
AU  - Verma R
FAU - Walia, Ritu
AU  - Walia R
FAU - Sondike, Stephen B
AU  - Sondike SB
FAU - Khan, Raheel
AU  - Khan R
LA  - eng
GR  - U54 GM104942/GM/NIGMS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - W V Med J
JT  - The West Virginia medical journal
JID - 0413777
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Crohn Disease/*drug therapy
MH  - Humans
MH  - Infliximab
MH  - Male
MH  - Nocardia Infections/drug therapy/*etiology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC5003015
MID - NIHMS749729
OID - NLM: NIHMS749729
OID - NLM: PMC5003015
EDAT- 2015/06/09 06:00
MHDA- 2015/06/20 06:00
CRDT- 2015/06/09 06:00
PHST- 2015/06/09 06:00 [entrez]
PHST- 2015/06/09 06:00 [pubmed]
PHST- 2015/06/20 06:00 [medline]
PST - ppublish
SO  - W V Med J. 2015 May-Jun;111(3):36-9.